BioMarin Pharmaceutical Inc. is wasting little time getting to the market with its newly approved enzyme-replacement therapy, Naglazyme, for patients with mucopolysaccharidosis VI. (BioWorld Today)

BioMarin Pharmaceutical Inc. is wasting little time getting to the market with its newly approved enzyme-replacement therapy, Naglazyme, for patients with mucopolysaccharidosis VI. (BioWorld Today)